Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice

Toxicology in Vitro

Volumn 29, Issue 7, 2015, Pages 1569-1576

  He, Wei ^a,b   Wu, Jing Jing ^c   Ning, Jing ^c,d   Hou, Jie ^d   Xin, Hong ^a,b   He, Yu Qi ^c   Ge, Guang Bo ^c   Xu, Wei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450 enzymes (CYPs); Herb drug interactions (HDIs); Human liver microsomes (HLMs); Inhibition; Licochalcone A (LCA)

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; LICOCHALCONE A; CHALCONE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; GLYCYRRHIZA; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; HERB DRUG INTERACTION; METABOLISM;

GLYCYRRHIZA;

CHALCONES; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; GLYCYRRHIZA; HERB-DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER;

EID: 84935028819     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2015.06.014     Document Type: Article

References (46)

1. Bode A.M., Dong Z. Chemopreventive effects of licorice and its components. Curr. Pharmacol. Rep. 2015, 1:60-71.
2. Buchanan C.M., Shih J.-H., Astin J.W., Rewcastle G.W., Flanagan J.U., Crosier P.S., Shepherd P.R. DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. Clin. Sci. 2012, 122:449-457.
3. Chang T.K., Waxman D.J. Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate. Cytochrome P450 Protocols 1998, 103-110. Springer.
4. Chen M., Theander T.G., Christensen S.B., Hviid L., Zhai L., Kharazmi A. Licochalcone-a, a new antimalarial agent, inhibits in-vitro growth of the human malaria parasite plasmodium-falciparum and protects mice from P-Yoelii infection. Antimicrob. Agents Chemother. 1994, 38:1470-1475.
5. Choi J., Choi D. Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Die Pharmazie - Int. J. Pharm. Sci. 2013, 68:882-888.
6. Daily E.B., Aquilante C.L. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009, 10:1489-1510.
7. Desai P.B., Duan J.Z., Zhu Y.W., Kouzi S. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur. J. Drug Metab. Pharmacokinet. 1998, 23:417-424.
8. Feldschuh J., Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977, 56:605-612.
9. Hasler J.A., Estabrook R., Murray M., Pikuleva I., Waterman M., Capdevila J., Holla V., Helvig C., Falck J.R., Farrell G. Human cytochromes P450. Mol. Aspects Med. 1999, 20:1-137.
10. Henderson M., Miranda C., Stevens J., Deinzer M., Buhler D. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica 2000, 30:235-251.
11. Hirth J., Watkins P.B., Strawderman M., Schott A., Bruno R., Baker L.H. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res. 2000, 6:1255-1258.
12. Hodek P., Trefil P., Stiborová M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem.-Biol. Int. 2002, 1-21.
13. Johansson M., Strahm E., Rane A., Ekström L. CYP2C8 and CYP2C9 mRNA expression profile in the human fetus. Front. Genet. 2014, 5.
14. Kenworthy K.E., Clarke S.E., Andrews J., Houston J.B. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos.: Biol. Fate Chem. 2001, 29:1644-1651.
15. Kirby B.J., Unadkat J.D. Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution. Drug Metab. Dispos.: Biol. Fate Chem. 2010, 38:1926-1933.
16. Komatsu T., Yamazaki H., Shimada N., Nakajima M., Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos. 2000, 28:1457-1463.
17. Kumar S., Samuel K., Subramanian R., Braun M.P., Stearns R.A., Chiu S.H.L., Evans D.C., Baillie T.A. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J. Pharmacol. Exp. Ther. 2002, 303:969-978.
18. Lai X.-S., Yang L.-P., Li X.-T., Liu J.-P., Zhou Z.-W., Zhou S.-F. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr. Drug Metab. 2009, 10:1009-1047.
19. Li X.Q., Bjorkman A., Andersson T.B., Ridderstrom M., Masimirembwa C.M. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 2002, 300:399-407.
20. Liu Y., Ramirez J., House L., Ratain M.J. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab. Dispos.: Biol. Fate Chem. 2010, 38:32-39.
21. Liu J.M., Wang Q.L., Yao T.W., Yang B.C. Research on distribution and dosage of liquorice. Chin. Arch. Tradit. Chin. Med. 2014, 32:3021-3024.
22. Miners J.O., Birkett D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998, 45:525-538.
23. Nakajima M., Kobayashi K., Shimada N., Tokudome S., Yamamoto T., Kuroiwa Y. Involvement of CYP1A2 in mexiletine metabolism. Br. J. Clin. Pharmacol. 1998, 46:55-62.
24. Narimatsu S., Takemi C., Tsuzuki D., Kataoka H., Yamamoto S., Shimada N., Suzuki S., Satoh T., Meyer U.A., Gonzalez F.J. Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes. J. Pharmacol. Exp. Ther. 2002, 303:172-178.
25. Nishio M., Matsuda M., Ohyanagi F., Sato Y., Okumura S., Tabata D., Morikawa A., Nakagawa K., Horai T. Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy. Lung Cancer 2005, 49:245-251.
26. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther. 2000, 294:88-95.
27. Obach R.S., Walsky R.L., Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos.: Biol. Fate Chem. 2007, 35:246-255.
28. Ono S., Hatanaka T., Hotta H., Tsutsui M., Satoh T., Gonzalez F.J. Chlorzoxazone is metabolized by human Cyp1a2 as well as by human Cyp2e1. Pharmacogenetics 1995, 5:143-150.
29. Qiao X., Ji S., Yu S.-w., Lin X.-h., Jin H.-w., Duan Y.-k., Zhang L.-r., Guo D.-a., Ye M. Identification of key licorice constituents which interact with cytochrome P450: evaluation by LC/MS/MS cocktail assay and metabolic profiling. AAPS J. 2014, 16:101-113.
30. Rafi M.M., Rosen R.T., Vassil A., Ho C.T., Zhang H., Ghai G., Lambert G., DiPaola R.S. Modulation of bcl-2 and cytotoxicity of licochalcone-A, a novel estrogenic flavonoid. Clin. Cancer Res. 1999, 5:3782S.
31. Rendic S., Nolteernsting E., Schänzer W. Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes: gas chromatographic-mass spectrometric determination of metabolites. J. Chromatogr. B Biomed. Sci. Appl. 1999, 735:73-83.
32. Shimada T., Tanaka K., Takenaka S., Murayama N., Martin M.V., Foroozesh M.K., Yamazaki H., Guengerich F.P., Komori M. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem. Res. Toxicol. 2010, 23:1921-1935.
33. Spaggiari D., Geiser L., Daali Y., Rudaz S. Phenotyping of CYP450 in human liver microsomes using the cocktail approach. Anal. Bioanal. Chem. 2014, 406:4875-4887.
34. Tsukamoto S., Aburatani M., Yoshida T., Yamashita Y., El-beih A.A., Ohta T. CYP3A4 inhibitors isolated from Licorice. Biol. Pharm. Bullet. 2005, 28:2000-2002.
35. Wang B., Sanchez R.I., Franklin R.B., Evans D.C., Huskey S.-E.W. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17α-ethinylestradiol. Drug Metab. Dispos. 2004, 32:1209-1212.
36. Wang X., Zhang H., Chen L., Shan L., Fan G., Gao X. Liquorice, a unique "guide drug" of traditional Chinese medicine: a review of its role in drug interactions. J. Ethnopharmacol. 2013, 150:781-790.
37. Wang H.-J., Pao L.-H., Hsiong C.-H., Shih T.-Y., Lee M.-S., Hu O.Y.-P. Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship. AAPS J. 2014, 16:258-268.
38. Wienkers L.C., Heath T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discovery 2005, 4:825-833.
39. Williams J.A., Hyland R., Jones B.C., Smith D.A., Hurst S., Goosen T.C., Peterkin V., Koup J.R., Ball S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 2004, 32:1201-1208.
40. Wrighton S.A., Stevens J.C. The human hepatic cytochromes P450 involved in drug metabolism. CRC Crit. Rev. Toxicol. 1992, 22:1-21.
41. Xie J., Zhang Y., Wang W. HPLC analysis of glycyrrhizin and licochalcone a in Glycyrrhiza inflata from Xinjiang (China). Chem. Nat. Compd. 2010, 46:148-151.
42. Yasui-Furukori N., Takahata T., Nakagami T., Yoshiya G., Inoue Y., Kaneko S., Tateishi T. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br. J. Clin. Pharmacol. 2004, 57:487-494.
43. Yuan Y., Qiu X., Nikolić D., Chen S.-N., Huang K., Li G., Pauli G.F., van Breemen R.B. Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols. Eur. J. Pharm. Sci. 2014, 53:55-61.
44. Zhai S., Dai R., Friedman F.K., Vestal R.E. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos. 1998, 26:989-992.
45. Zhang Q., Ye M. Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). J. Chromatogr. A 2009, 1216:1954-1969.
46. Zhou S.-F., Zhou Z.-W., Li C.-G., Chen X., Yu X., Xue C.C., Herington A. Identification of drugs that interact with herbs in drug development. Drug Discovery Today 2007, 12:664-673.